NBIX

#766
Neurocrine Biosciences Inc
133.2500 USD
+3.77%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
133.2500
133.2500
Range Annuel
122.1375
160.1800
Changement quotidien
+3.77%
Changement Mensuel
+2.17%
Evolution sur 6 mois
-8.10%
Changement Annuel
-8.10%
Clôture Précédente
128.4100
Open
133.2500
Bid
Ask
Low
133.2500
High
133.2500
Volume
134
Open full chart

Financials

Overview Relevé Statistics
Quarterly Annual
  • Market Capitalization 13.3734 B
  • Employee 2 000
  • Founded 1992
  • CEO Kevin C. Gorman
  • Website www.neurocrine.com
  • Headquarter Delaware, United States
  • FIGI BBG000GJS7C1
  • Industry Fabricants de Médicaments — Spécialités et Génériques
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
30.37
Price to sales ratio
5.08

Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

Nouvelles